×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
PIRS – pieris pharmaceuticals, inc. (US:AMEX)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
PIRS
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
10/17
07:30 am
pirs
Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer
Low
Report
Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer
10/3
07:49 am
pirs
Palvella Therapeutics Awarded Up to $2.6 million Grant from the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development to Support Phase 3 Single-Arm, Baseline-Controlled Trial in Microcystic Lymphatic Malformations [Yahoo! Finance]
Low
Report
Palvella Therapeutics Awarded Up to $2.6 million Grant from the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development to Support Phase 3 Single-Arm, Baseline-Controlled Trial in Microcystic Lymphatic Malformations [Yahoo! Finance]
9/3
02:03 pm
pirs
PIRS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Pieris Pharmaceuticals, Inc. Is Fair to Shareholders
Medium
Report
PIRS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Pieris Pharmaceuticals, Inc. Is Fair to Shareholders
8/19
06:38 am
pirs
Pieris Pharmaceuticals Second Quarter 2024 Earnings: US$2.76 loss per share (vs US$3.63 profit in 2Q 2023) [Yahoo! Finance]
Low
Report
Pieris Pharmaceuticals Second Quarter 2024 Earnings: US$2.76 loss per share (vs US$3.63 profit in 2Q 2023) [Yahoo! Finance]
8/17
09:24 am
pirs
We're A Little Worried About Pieris Pharmaceuticals' (NASDAQ:PIRS) Cash Burn Rate [Yahoo! Finance]
High
Report
We're A Little Worried About Pieris Pharmaceuticals' (NASDAQ:PIRS) Cash Burn Rate [Yahoo! Finance]
8/16
11:05 pm
pirs
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
High
Report
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
8/16
07:30 pm
pirs
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PIRS, ENV, AFBI on Behalf of Shareholders
High
Report
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PIRS, ENV, AFBI on Behalf of Shareholders
8/16
03:42 pm
pirs
SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Merger of Pieris Pharmaceuticals, Inc. - PIRS
Low
Report
SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Merger of Pieris Pharmaceuticals, Inc. - PIRS
Date
Time
Symbol
Company Name
Action
%Chg
11/14/2023
04:02 pm
pirs
pieris pharmaceuticals, inc.
IN-LINE
Report
-7.4%
pieris pharmaceuticals, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/5
05:02 pm
pirs
Form S-4/A PIERIS PHARMACEUTICALS,
Low
Report
Form S-4/A PIERIS PHARMACEUTICALS,
10/29
08:46 am
pirs
Form S-4/A PIERIS PHARMACEUTICALS,
Low
Report
Form S-4/A PIERIS PHARMACEUTICALS,
10/28
05:19 pm
pirs
Form 4 PIERIS PHARMACEUTICALS, For: Aug 07 Filed by: GERAGHTY JAMES A
Low
Report
Form 4 PIERIS PHARMACEUTICALS, For: Aug 07 Filed by: GERAGHTY JAMES A
10/17
08:00 am
pirs
Form 425 PIERIS PHARMACEUTICALS, Filed by: PIERIS PHARMACEUTICALS, INC.
Low
Report
Form 425 PIERIS PHARMACEUTICALS, Filed by: PIERIS PHARMACEUTICALS, INC.
10/15
08:31 am
pirs
Form S-4/A PIERIS PHARMACEUTICALS,
Low
Report
Form S-4/A PIERIS PHARMACEUTICALS,
10/15
08:01 am
pirs
Form 425 PIERIS PHARMACEUTICALS, Filed by: PIERIS PHARMACEUTICALS, INC.
Neutral
Report
Form 425 PIERIS PHARMACEUTICALS, Filed by: PIERIS PHARMACEUTICALS, INC.
10/3
08:01 am
pirs
Form 425 PIERIS PHARMACEUTICALS, Filed by: PIERIS PHARMACEUTICALS, INC.
Low
Report
Form 425 PIERIS PHARMACEUTICALS, Filed by: PIERIS PHARMACEUTICALS, INC.
10/3
08:00 am
pirs
Form 8-K PIERIS PHARMACEUTICALS, For: Oct 03
Low
Report
Form 8-K PIERIS PHARMACEUTICALS, For: Oct 03
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/13
Pieris Pharmaceuticals Inc (NASDAQ: PIRS) was upgraded by analysts at Robert W. Baird from a "neutral" rating to an "outperform" rating.
34.2%
7/30 Pieris Pharmaceuticals Inc (NASDAQ: PIRS) was downgraded by analysts at Robert W. Baird from an "outperform" rating to a "neutral" rating. 13.7%
7/26 Form 4 PIERIS PHARMACEUTICALS, For: Jul 25 Filed by: Richman Michael 12.2%
11/5 Pieris Pharmaceuticals to Present Phase 1 Data for 4-1BB/HER2 Bispecific PRS-343 at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 11.5%
5/13 Pieris Pharmaceuticals Inc (NASDAQ: PIRS) is now covered by analysts at Robert W. Baird. They set an "outperform" rating on the stock. 9.9%
3/18 Pieris Pharmaceuticals Inc (NASDAQ: PIRS) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. 9.7%
11/4 Pieris Pharmaceuticals to Host Third Quarter 2019 Investor Call and Corporate Update on November 11, 2019 9.0%
3/23 Pieris Pharmaceuticals Provides Update on Servier Collaboration 8.1%
11/13 Pieris Pharmaceuticals Inc (NASDAQ: PIRS) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. 7.9%
5/10 Form 10-Q PIERIS PHARMACEUTICALS, For: Mar 31 7.3%
7/30 Pieris Pharmaceuticals Inc (NASDAQ: PIRS) was downgraded by analysts at Robert W. Baird from an "outperform" rating to a "neutral" rating. 13.7%
7/26 Form 4 PIERIS PHARMACEUTICALS, For: Jul 25 Filed by: Richman Michael 12.2%
11/5 Pieris Pharmaceuticals to Present Phase 1 Data for 4-1BB/HER2 Bispecific PRS-343 at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 11.5%
5/13 Pieris Pharmaceuticals Inc (NASDAQ: PIRS) is now covered by analysts at Robert W. Baird. They set an "outperform" rating on the stock. 9.9%
3/18 Pieris Pharmaceuticals Inc (NASDAQ: PIRS) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. 9.7%
11/4 Pieris Pharmaceuticals to Host Third Quarter 2019 Investor Call and Corporate Update on November 11, 2019 9.0%
3/23 Pieris Pharmaceuticals Provides Update on Servier Collaboration 8.1%
11/13 Pieris Pharmaceuticals Inc (NASDAQ: PIRS) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. 7.9%
5/10 Form 10-Q PIERIS PHARMACEUTICALS, For: Mar 31 7.3%
TOP News Decliners
3/12
Pieris Pharmaceuticals Reports Full-Year 2019 Financial Results And Provides Corporate Update
-26.8%
9/27 Form 8-K PIERIS PHARMACEUTICALS, For: Sep 27 -18.5%
9/26 Pieris Pharmaceuticals Inc (NASDAQ: PIRS) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -17.1%
11/12 Form 424B5 PIERIS PHARMACEUTICALS, -15.5%
3/18 Pieris Pharmaceuticals Inc (NASDAQ: PIRS) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -12.9%
3/27 Pieris Pharmaceuticals Inc (NASDAQ: PIRS) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $2.50 price target on the stock. -11.1%
12/4 Form S-3 PIERIS PHARMACEUTICALS, -9.7%
3/13 Form 10-K PIERIS PHARMACEUTICALS, For: Dec 31 -8.8%
7/31 Form 8-K PIERIS PHARMACEUTICALS, For: Jul 31 -8.7%
9/23 Form 8-K PIERIS PHARMACEUTICALS, For: Sep 20 -8.5%
9/27 Form 8-K PIERIS PHARMACEUTICALS, For: Sep 27 -18.5%
9/26 Pieris Pharmaceuticals Inc (NASDAQ: PIRS) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -17.1%
11/12 Form 424B5 PIERIS PHARMACEUTICALS, -15.5%
3/18 Pieris Pharmaceuticals Inc (NASDAQ: PIRS) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -12.9%
3/27 Pieris Pharmaceuticals Inc (NASDAQ: PIRS) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $2.50 price target on the stock. -11.1%
12/4 Form S-3 PIERIS PHARMACEUTICALS, -9.7%
3/13 Form 10-K PIERIS PHARMACEUTICALS, For: Dec 31 -8.8%
7/31 Form 8-K PIERIS PHARMACEUTICALS, For: Jul 31 -8.7%
9/23 Form 8-K PIERIS PHARMACEUTICALS, For: Sep 20 -8.5%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: